Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NBEV Stock Summary
In the News
Former CEO of NewAge, a drink company that shot to pot-stock fame, accused by SEC of ‘multi-year fraud'
The Securities and Exchange Commission has filed charges against former NewAge Inc. Chief Executive Brent David Willis, accusing him of a “multi-year fraud” that included misleading public statements meant to promote the wellness-focused beverage maker that once hoped to take advantage of the nation's CBD craze.
7 Penny Stocks That Actually Have a Buy Rating
Finding penny stocks with buy ratings is becoming increasingly difficult. The higher interest rates go, the more risk-averse the markets become.
Hot Penny Stocks to Buy After the Long Weekend? 3 to Watch
Which penny stocks are on your watchlist today? The post Hot Penny Stocks to Buy After the Long Weekend?
Which Strategies Are You Using With Penny Stocks in September?
Are you using these strategies for trading penny stocks right now? The post Which Strategies Are You Using With Penny Stocks in September?
7 Penny Stocks to Sell Before They Go to Zero
The first half of 2022 for the stock market was the worst since 1970. Consequently, investors are forced to re-evaluate their portfolios and discard risky assets.
Trending Penny Stocks to Buy in September? 3 For Your List
Which penny stocks are you watching today? The post Trending Penny Stocks to Buy in September?
New Age: Four Catalysts That We Like Including A Valuation That Is Too Cheap To Ignore
Once high-flying New Age has had its wings clipped and continues to suffer a hangover from the disasterous Brent Willis era. With Willis now gone, Interim CEO John Brennan is attempting to breathe new life into the company and has taken steps in an effort to increase shareholder value.
NewAge, Inc. Delays Fourth Quarter and Full Year 2021 Financial Results Conference Call
SALT LAKE CITY, March 15, 2022 (GLOBE NEWSWIRE) -- NewAge, Inc. (Nasdaq: NBEV), a direct selling company with a primary focus on healthy products, today announced its fourth quarter and full year 2021 earnings release and conference call will be rescheduled to allow additional time to complete its Annual Report on Form 10-K. The Company will be filing a Form 12b-25, Notification of Late Filing, on March 16, 2022, which will provide the Company with a 15-day extension to file its Form 10-K. The Company expects to report financial results for the quarter and full year ended December 31, 2021, on or before March 31, 2022, the expiration date of the extension period. Updated conference call details will be provided in a subsequent announcement.
NewAge to weigh reverse stock split to regain Nasdaq listing requirement
NewAge Inc. NBEV, -0.14% said Friday it has received notice from Nasdaq Stock Market LLC that it is not in compliance with the $1.00 closing bid listing requirement. The Utah-based health and wellness beverage and cannabis company has 180 days, until Aug. 23, to regain compliance or its stock will be delisted.
NewAge, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 16
SALT LAKE CITY, Feb. 25, 2022 (GLOBE NEWSWIRE) -- NewAge, Inc. (Nasdaq: NBEV), a direct-to-consumer (D2C) healthy products company, today announced that it will release financial results for its fourth quarter and full year ended December 31, 2021, after the market close on Wednesday, March 16, 2022.
NBEV Financial details
NBEV Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2020-12-31
Metric | History | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.34 | 1.7 | 1.12 | 3.28 | 2.9 | |
Net income per share | -0.19 | -0.12 | -0.26 | -1.16 | -0.41 | |
Operating cash flow per share | 0.05 | -0.27 | -0.47 | -0.41 | -0.36 | |
Free cash flow per share | 0.05 | -0.29 | -0.49 | -0.5 | -0.38 | |
Cash per share | 0.03 | 0.01 | 0.92 | 0.79 | 0.45 | |
Book value per share | 0.26 | 1.72 | 3.33 | 1.19 | 1.5 | |
Tangible book value per share | -0.24 | 0.26 | 1.19 | 0.5 | -1.49 | |
Share holders equity per share | 0.26 | 1.72 | 3.33 | 1.19 | 1.5 | |
Interest debt per share | 0.81 | 0.12 | 0.12 | 0.36 | 0.38 | |
Market cap | 73.29M | 66.44M | 241.53M | 140.6M | 253.4M | |
Enterprise value | 87.73M | 73.64M | 203.71M | 103.77M | 243.88M | |
P/E ratio | -20.17 | -18.79 | -19.9 | -1.57 | -6.44 | |
Price to sales ratio | 2.9 | 1.27 | 4.63 | 0.55 | 0.91 | |
POCF ratio | 75.16 | -7.9 | -11.06 | -4.42 | -7.4 | |
PFCF ratio | 78.98 | -7.4 | -10.7 | -3.61 | -6.9 | |
P/B Ratio | 15.02 | 1.26 | 1.56 | 1.52 | 1.76 | |
PTB ratio | 15.02 | 1.26 | 1.56 | 1.52 | 1.76 | |
EV to sales | 3.47 | 1.41 | 3.91 | 0.41 | 0.87 | |
Enterprise value over EBITDA | -31.22 | -43.28 | -11.52 | -1.61 | -8.15 | |
EV to operating cash flow | 89.96 | -8.76 | -9.33 | -3.26 | -7.12 | |
EV to free cash flow | 94.54 | -8.21 | -9.02 | -2.66 | -6.64 | |
Earnings yield | -0.05 | -0.05 | -0.05 | -0.64 | -0.16 | |
Free cash flow yield | 0.01 | -0.14 | -0.09 | -0.28 | -0.14 | |
Debt to equity | 3.07 | 0.06 | 0.03 | 0.26 | 0.24 | |
Debt to assets | 0.56 | 0.05 | 0.02 | 0.1 | 0.09 | |
Net debt to EBITDA | -5.14 | -4.23 | 2.14 | 0.57 | 0.32 | |
Current ratio | 0.87 | 1.46 | 1.74 | 1.42 | 1.04 | |
Interest coverage | -12.13 | -26.53 | -18.14 | -20.49 | -14.63 | |
Income quality | -0.27 | 2.38 | 1.8 | 0.35 | 0.87 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.31 | 0.28 | 0.39 | 0 | 0.41 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.35 | 0.66 | 0.35 | 0.21 | 0.59 | |
Capex to operating cash flow | -0.05 | 0.07 | 0.03 | 0.23 | 0.07 | |
Capex to revenue | 0 | -0.01 | -0.01 | -0.03 | -0.01 | |
Capex to depreciation | -0.09 | -0.35 | -0.32 | -0.82 | -0.28 | |
Stock based compensation to revenue | 0 | 0.03 | 0.05 | 0.03 | 0.02 | |
Graham number | 1.06 | 2.12 | 4.42 | 5.59 | 3.71 | |
ROIC | -0.2 | -0.18 | -0.06 | -0.59 | -0.15 | |
Return on tangible assets | -0.21 | -0.15 | -0.06 | -0.46 | -0.25 | |
Graham Net | -0.82 | -0.18 | -1.36 | -0.92 | -2.3 | |
Working capital | -1.44M | 5.11M | 40.91M | 33.53M | 4.59M | |
Tangible asset value | -4.56M | 7.95M | 55.19M | 38.55M | -143.72M | |
Net current asset value | -11.84M | 1.29M | -36.42M | -45.9M | -171.79M | |
Invested capital | 3.07 | 0.06 | 0.03 | 0.26 | 0.24 | |
Average receivables | 2.49M | 6.1M | 9.22M | 11.06M | 11.74M | |
Average payables | 3.58M | 5.63M | 6.67M | 11.11M | 18.02M | |
Average inventory | 2.31M | 5.73M | 22.09M | 36.93M | 42.38M | |
Days sales outstanding | 68.22 | 52.19 | 76.84 | 16.02 | 16.12 | |
Days payables outstanding | 128.75 | 40.09 | 76.3 | 47.92 | 81.51 | |
Days of inventory on hand | 82.72 | 64.6 | 316.32 | 132.69 | 171.98 | |
Receivables turnover | 5.35 | 6.99 | 4.75 | 22.79 | 22.65 | |
Payables turnover | 2.83 | 9.1 | 4.78 | 7.62 | 4.48 | |
Inventory turnover | 4.41 | 5.65 | 1.15 | 2.75 | 2.12 | |
ROE | -0.74 | -0.07 | -0.08 | -0.97 | -0.27 | |
Capex per share | 0 | -0.02 | -0.02 | -0.09 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2021-09-30 for Q3
Metric | History | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.64 | 0.92 | 0.99 | 0.86 | 0.66 | |
Net income per share | -0.14 | 0 | -0.14 | 0.12 | -0.02 | |
Operating cash flow per share | -0.06 | -0.04 | -0.02 | -0.02 | -0.13 | |
Free cash flow per share | -0.07 | -0.05 | -0.02 | -0.03 | -0.14 | |
Cash per share | 0.27 | 0.45 | 0.71 | 0.56 | 0.31 | |
Book value per share | 0.86 | 1.47 | 1.32 | 1.55 | 1.47 | |
Tangible book value per share | 0.35 | -1.47 | -0.41 | 0.02 | 0.15 | |
Share holders equity per share | 0.86 | 1.47 | 1.32 | 1.55 | 1.47 | |
Interest debt per share | 0.21 | 0.36 | 0.59 | 0.58 | 0.48 | |
Market cap | 169.23M | 257.26M | 363.96M | 320.31M | 210.46M | |
Enterprise value | 162.31M | 247.75M | 345.12M | 319.56M | 233.99M | |
P/E ratio | -2.99 | -15.92K | -5.12 | 4.61 | -19.49 | |
Price to sales ratio | 2.7 | 2.85 | 2.9 | 2.58 | 2.11 | |
POCF ratio | -27.05 | -58.5 | -169.99 | -93.68 | -10.5 | |
PFCF ratio | -26.5 | -54.04 | -149.9 | -82.19 | -10.24 | |
P/B Ratio | 2.01 | 1.78 | 2.16 | 1.44 | 0.95 | |
PTB ratio | 2.01 | 1.78 | 2.16 | 1.44 | 0.95 | |
EV to sales | 2.59 | 2.74 | 2.75 | 2.58 | 2.35 | |
Enterprise value over EBITDA | -14.56 | 1.1K | -41.24 | 12.28 | 49.87 | |
EV to operating cash flow | -25.94 | -56.33 | -161.19 | -93.47 | -11.67 | |
EV to free cash flow | -25.42 | -52.04 | -142.14 | -82 | -11.38 | |
Earnings yield | -0.08 | 0 | -0.05 | 0.05 | -0.01 | |
Free cash flow yield | -0.04 | -0.02 | -0.01 | -0.01 | -0.1 | |
Debt to equity | 0.24 | 0.24 | 0.43 | 0.36 | 0.32 | |
Debt to assets | 0.09 | 0.09 | 0.15 | 0.18 | 0.17 | |
Net debt to EBITDA | 0.62 | -42.1 | 2.25 | -0.03 | 5.02 | |
Current ratio | 1.41 | 1.04 | 1.43 | 1.5 | 1.42 | |
Interest coverage | -25.23 | -3.72 | -1.02 | -3.11 | -12.05 | |
Income quality | 0.44 | 1.09K | 0.12 | -0.2 | 7.43 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 1.25 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.23 | 0.59 | 0.47 | 0.48 | 0.49 | |
Capex to operating cash flow | 0.02 | 0.08 | 0.13 | 0.14 | 0.03 | |
Capex to revenue | 0 | 0 | 0 | 0 | -0.01 | |
Capex to depreciation | -0.07 | -0.11 | -0.06 | -0.1 | -0.11 | |
Stock based compensation to revenue | 0.02 | 0.01 | 0.02 | 0.02 | 0.01 | |
Graham number | 1.67 | 0.04 | 2.04 | 2.05 | 0.77 | |
ROIC | -0.1 | 10.92 | -0.01 | -0.03 | -0.1 | |
Return on tangible assets | -0.08 | 0 | -0.07 | 0.07 | -0.01 | |
Graham Net | -0.87 | -2.27 | -1.38 | -0.83 | -0.7 | |
Working capital | 21.29M | 4.59M | 47.2M | 53.95M | 40.78M | |
Tangible asset value | 33.99M | -143.72M | -52.68M | 3.23M | 22.95M | |
Net current asset value | -61.91M | -171.79M | -140.26M | -68.5M | -44.96M | |
Invested capital | 0.24 | 0.24 | 0.43 | 0.36 | 0.32 | |
Average receivables | 11.76M | 11.34M | 12.26M | 11.33M | 9.67M | |
Average payables | 11.65M | 16.69M | 19.54M | 16.71M | 17.55M | |
Average inventory | 32.27M | 39.31M | 45.5M | 43.58M | 46.55M | |
Days sales outstanding | 14.83 | 12.28 | 8.74 | 7.6 | 8.02 | |
Days payables outstanding | 37.81 | 68.25 | 38.51 | 38.27 | 48.25 | |
Days of inventory on hand | 109.06 | 144.01 | 101.4 | 98.9 | 131.05 | |
Receivables turnover | 6.07 | 7.33 | 10.3 | 11.85 | 11.22 | |
Payables turnover | 2.38 | 1.32 | 2.34 | 2.35 | 1.87 | |
Inventory turnover | 0.83 | 0.62 | 0.89 | 0.91 | 0.69 | |
ROE | -0.17 | 0 | -0.11 | 0.08 | -0.01 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
NBEV Frequently Asked Questions
What is NewAge, Inc. stock symbol ?
NewAge, Inc. is a US stock , located in Denver of Colorado and trading under the symbol NBEV
What is NewAge, Inc. stock quote today ?
NewAge, Inc. stock price is $- today.
Is NewAge, Inc. stock public?
Yes, NewAge, Inc. is a publicly traded company.